© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 3, 219-225,
February 7, 2001
© 2001 Oxford University Press
REPORT |
Association of African-American Ethnic Background With Survival in Men With Metastatic Prostate Cancer
Affiliations of authors: I. M. Thompson, A. Tolcher, The University of Texas Health Sciences Center at San Antonio; C. M. Tangen, C. M. Moinpour, The Southwest Oncology Group Statistical Center, Seattle, WA; E. D. Crawford, The University of Colorado Health Sciences Center, Denver; M. Eisenberger, The Johns Hopkins University, Baltimore, MD.
Correspondence to: Ian M. Thompson, M.D., Division of Urology, The University of Texas Health Sciences Center at San Antonio, MC 7845, 7703 Floyd Curl Dr., San Antonio, TX 78229–3900 (e-mail: thompsoni{at}uthscsa.edu).Reprint requests to: Southwest Oncology Group (SWOG-8894), Operations Office, 14980 Omicron Dr., San Antonio, TX 78245–3217.
Background: African-American men have earlier onset of prostate cancer, higher prostate-specific antigen (PSA) levels, more advanced stage at diagnosis, and higher mortality than white men. It is not known whether the poorer survival of African-American men with prostate cancer reflects their later stage at diagnosis or differences in the basic biology of their disease. To evaluate this question, we examined outcomes of African-American and white men with metastatic prostate cancer in the context of a randomized clinical trial. Methods: Southwest Oncology Group Study 8894 was a randomized phase III trial that compared orchiectomy with or without flutamide in men with metastatic prostate cancer. Using data from 288 African-American and 975 white men in the trial, we conducted a proportional hazards regression analysis to determine if ethnicity was an independent predictor of survival. All statistical tests were two-sided. Results: African-American men were more likely than white men to have extensive disease and bone pain and had poorer performance status, younger age at study entry, higher Gleason score, and higher PSA levels. After adjustment for these prognostic variables, the hazard ratio (HR) for all-cause mortality for African-American men relative to white men was 1.23 (P = .018). Further adjustment for initial quality-of-life assessments also resulted in higher HRs associated with African-American ethnicity relative to white ethnicity (HR = 1.39; P = .007). Conclusions: African-American men with metastatic prostate cancer have a statistically significantly worse prognosis than white men that cannot be explained by the prognostic variables explored in this study. These data should give increased impetus for efforts to detect the disease early in African-American men and for the development of more effective therapies based on potential biologic differences in this ethnic group.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Uhlman, J. W. Moul, P. Tang, D. A. Stackhouse, and L. Sun Review: Risk stratification in the hormonal treatment of patients with prostate cancer Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 79 - 94. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Beuten, J. A.L. Gelfond, J. J. Byrne, I. Balic, A. C. Crandall, T. L. Johnson-Pais, I. M. Thompson, D. K. Price, and R. J. Leach CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians Carcinogenesis, September 1, 2008; 29(9): 1751 - 1757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Consedine, B. A. Adjei, P. M. Ramirez, and J. M. McKiernan An Object Lesson: Source Determines the Relations That Trait Anxiety, Prostate Cancer Worry, and Screening Fear Hold with Prostate Screening Frequency Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1631 - 1639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Schwartz Prostate Cancer, Serum Parathyroid Hormone, and the Progression of Skeletal Metastases Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 478 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Wallace, R. L. Prueitt, M. Yi, T. M. Howe, J. W. Gillespie, H. G. Yfantis, R. M. Stephens, N. E. Caporaso, C. A. Loffredo, and S. Ambs Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men Cancer Res., February 1, 2008; 68(3): 927 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Shook, J. Beuten, K. C. Torkko, T. L. Johnson-Pais, D. A. Troyer, I. M. Thompson, and R. J. Leach Association of RNASEL Variants with Prostate Cancer Risk in Hispanic Caucasians and African Americans Clin. Cancer Res., October 1, 2007; 13(19): 5959 - 5964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Gebhardt Perspectives on Health Disparities in Orthopaedic Oncology J. Am. Acad. Ortho. Surg., September 1, 2007; 15(suppl_1): S5 - S7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Robbins, D. Yin, and A. Parikh-Patel Differences in Prognostic Factors and Survival among White Men and Black Men with Prostate Cancer, California, 1995-2004 Am. J. Epidemiol., July 1, 2007; 166(1): 71 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Nock, D. Tang, A. Rundle, C. Neslund-Dudas, A. T. Savera, C. H. Bock, K. G. Monaghan, A. Koprowski, N. Mitrache, J. J. Yang, et al. Associations between Smoking, Polymorphisms in Polycyclic Aromatic Hydrocarbon (PAH) Metabolism and Conjugation Genes and PAH-DNA Adducts in Prostate Tumors Differ by Race Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1236 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Consedine, D. Horton, T. Ungar, A. K. Joe, P. Ramirez, and L. Borrell Fear, Knowledge, and Efficacy Beliefs Differentially Predict the Frequency of Digital Rectal Examination Versus Prostate Specific Antigen Screening in Ethnically Diverse Samples of Older Men American Journal of Men's Health, March 1, 2007; 1(1): 29 - 43. [Abstract] [PDF]
|
|
|
|
|
|
N. S. Consedine, A. H. Morgenstern, E. Kudadjie-Gyamfi, C. Magai, and A. I. Neugut Prostate cancer screening behavior in men from seven ethnic groups: the fear factor. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 228 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saleem, V. M. Adhami, N. Ahmad, S. Gupta, and H. Mukhtar Prognostic Significance of Metastasis-Associated Protein S100A4 (Mts1) in Prostate Cancer Progression and Chemoprevention Regimens in an Autochthonous Mouse Model Clin. Cancer Res., January 1, 2005; 11(1): 147 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Godley, A. P. Schenck, M. A. Amamoo, V. J. Schoenbach, S. Peacock, M. Manning, M. Symons, and J. A. Talcott Racial Differences in Mortality Among Medicare Recipients After Treatment for Localized Prostate Cancer J Natl Cancer Inst, November 19, 2003; 95(22): 1702 - 1710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chen, B. A. Miller, E. Giovannucci, and R. B. Hayes Height and the Survival of Prostate Cancer Patients Cancer Epidemiol. Biomarkers Prev., March 1, 2003; 12(3): 215 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ntais, A. Polycarpou, and J. P. A. Ioannidis Association of the CYP17 Gene Polymorphism with the Risk of Prostate Cancer: A Meta-Analysis Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 120 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gupta, T. Hussain, G. T. MacLennan, P. Fu, J. Patel, and H. Mukhtar Differential Expression of S100A2 and S100A4 During Progression of Human Prostate Adenocarcinoma J. Clin. Oncol., January 1, 2003; 21(1): 106 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Bach, D. Schrag, O. W. Brawley, A. Galaznik, S. Yakren, and C. B. Begg Survival of Blacks and Whites After a Cancer Diagnosis JAMA, April 24, 2002; 287(16): 2106 - 2113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Polednak Re: Association of African-American Ethnic Background With Survival in Men With Metastatic Prostate Cancer J Natl Cancer Inst, August 1, 2001; 93(15): 1174 - 1175. [Full Text] [PDF]
|
|